Sugi Predict

Sugi Predict / Compounds / SCHEMBL21058353

SCHEMBL21058353

SCHEMBL21058353

CCCC(=O)N[C@H]1C(O)O[C@H](COC(=O)C(Cc2ccccc2)NC(=O)OC(C)(C)C)[C@@H](O)[C@@H]1O

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 3/20 0.48
▸ KLK5 Q9Y337 1/20 0.44
▸ CTSS P25774 3/20 0.43
▸ CTSK P43235 3/20 0.43
▸ CTSL P07711 2/20 0.43
▸ CTSB P07858 1/20 0.43
▸ EPHX2 P34913 1/20 0.42
▸ APP P05067 1/20 0.41
▸ MLYCD O95822 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ AKT1 P31749 1/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ PPARG P37231 1/20 0.39
▸ PPARA Q07869 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777479 1.00 ACE (0.48) ACEKLK5CTSSCTSKCTSL
SCHEMBL21058382 0.90 ITGB3 (0.38) ACEKLK5CTSSCTSKCTSL
SCHEMBL21138668 0.90 ITGB3 (0.38) ACEKLK5CTSSCTSKCTSL
SCHEMBL25957442 0.86 CTSK (0.36) ACECTSSCTSKKMT2A
SCHEMBL31353010 0.84 CAPN1 (0.40) CTSSCTSKCTSLCTSBMAPK1
SCHEMBL21137857 0.82 HK1 (0.41) —
Hydrochloric Acid SCHEMBL21058355 0.81 HK1 (0.40) —
SCHEMBL21058397 0.80 CTSK (0.35) KLK5CTSSCTSKCTSLCTSB
SCHEMBL21137891 0.80 CTSK (0.35) KLK5CTSSCTSKCTSLCTSB
SCHEMBL31352995 0.78 SSTR3 (0.46) KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2026-02-17 — — US disclosed
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2025-11-20 — — US disclosed
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2025-05-27 — — US disclosed
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2024-02-15 — — US disclosed
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-08-08 — — US disclosed
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN SUZHOU PHARMA TECH CO LTD (CN) 2023-07-20 — — US disclosed
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2023-02-28 — — US disclosed
CN-115594724-A Glucosamine derivatives for preventing or treating joint diseases 润佳（苏州）医药科技有限公司（CN） 2023-01-13 — — CN disclosed
CN-115215911-A Glucosamine derivative, composition thereof and medical application thereof 润佳（苏州）医药科技有限公司 2022-10-21 — — CN disclosed
CN-111971290-B Glucosamine derivatives for preventing or treating joint diseases 润佳（苏州）医药科技有限公司 2022-10-14 — — CN disclosed
CN-109929001-B Glucosamine derivative, composition thereof and medical application thereof 润佳（苏州）医药科技有限公司 2022-07-08 — — CN disclosed
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS Risen (Suzhou) Pharma Tech Co., Ltd. (CN) 2021-03-18 — — US disclosed
CN-111971290-A Glucosamine derivatives for preventing or treating joint diseases 润佳（苏州）医药科技有限公司 2020-11-20 — — CN disclosed
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353870-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA ACE 605/4885KLK5 1612/4885CTSS 674/4885
US-20210079033-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, GLA ACE 1293/4885KLK5 2168/4885CTSS 1085/4885
US-20240051982-A1 GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS OGT, UGGT1, FUT6 ACE 925/4885KLK5 2431/4885CTSS 1129/4885
US-11718636-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, GLA ACE 1293/4885KLK5 2168/4885CTSS 1085/4885
US-12552823-B2 Glucosamine derivatives and pharmaceutical uses thereof SOST, FUT6, SLC5A1 ACE 1734/4885KLK5 2328/4885CTSS 1006/4885
US-20230227488-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA ACE 605/4885KLK5 1612/4885CTSS 674/4885
US-20190185502-A1 GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF OGT, UGGT1, GLA ACE 605/4885KLK5 1612/4885CTSS 674/4885
US-11591358-B2 Glucosamine derivatives and pharmaceutical uses thereof OGT, UGGT1, GLA ACE 605/4885KLK5 1612/4885CTSS 674/4885
US-12312378-B2 Glucosamine derivatives for the prevention or treatment of joint disorders OGT, UGGT1, FUT6 ACE 925/4885KLK5 2431/4885CTSS 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback